Optimizing Furosemide Use in Advanced CKD: Balancing Risks and Benefits.
作者信息
Hannedouche Thierry, Ingwiller Maxime
机构信息
Renal Research Division, AURAL-Strasbourg, Strasbourg, France.
Department of Nephrology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
出版信息
Kidney Int Rep. 2025 Jun 3;10(8):2877. doi: 10.1016/j.ekir.2025.05.047. eCollection 2025 Aug.
Abstract
摘要
相似文献
1
Optimizing Furosemide Use in Advanced CKD: Balancing Risks and Benefits.优化晚期慢性肾脏病中呋塞米的使用：权衡风险与获益
Kidney Int Rep. 2025 Jun 3;10(8):2877. doi: 10.1016/j.ekir.2025.05.047. eCollection 2025 Aug.
2
Response to the Letter to the Editor Entitled "Optimizing Furosemide Use in Advanced CKD: Balancing Risks and Benefits".对题为《优化晚期慢性肾脏病中呋塞米的使用：权衡风险与获益》的致编辑信的回复
Kidney Int Rep. 2025 Jun 3;10(8):2877-2878. doi: 10.1016/j.ekir.2025.05.048. eCollection 2025 Aug.
3
Anticoagulation in Patients with End-Stage Renal Disease: A Critical Review.终末期肾病患者的抗凝治疗：一项批判性综述。
Healthcare (Basel). 2025 Jun 8;13(12):1373. doi: 10.3390/healthcare13121373.
4
Furosemide and Serum Protein-Bound Uremic Toxin Concentrations in Patients With CKD.慢性肾脏病患者中呋塞米与血清蛋白结合尿毒症毒素浓度
Kidney Int Rep. 2025 May 2;10(7):2165-2177. doi: 10.1016/j.ekir.2025.04.040. eCollection 2025 Jul.
5
Proton pump inhibitors in systemic sclerosis: should we exercise caution? Insights from a large-scale data analysis.系统性硬化症中的质子泵抑制剂：我们应该谨慎使用吗？来自大规模数据分析的见解。
Clin Rheumatol. 2025 Sep 12. doi: 10.1007/s10067-025-07686-4.
6
Depressive Symptoms, Antidepressants, and Clinical Outcomes in Chronic Kidney Disease: Findings from the CRIC Study.慢性肾脏病中的抑郁症状、抗抑郁药与临床结局：慢性肾脏病队列研究（CRIC）的结果
Kidney Med. 2024 Feb 9;6(4):100790. doi: 10.1016/j.xkme.2024.100790. eCollection 2024 Apr.
7
The impact of household air pollution from solid fuel use on rapid decline in kidney function and chronic kidney disease: A nationwide longitudinal cohort study.使用固体燃料造成的家庭空气污染对肾功能快速下降和慢性肾病的影响：一项全国性纵向队列研究。
J Nutr Health Aging. 2025 Aug 1;29(10):100641. doi: 10.1016/j.jnha.2025.100641.
8
Statins and kidney health: exploring cardiovascular benefits, renal protection, and risks in chronic kidney disease.他汀类药物与肾脏健康：探索慢性肾脏病中的心血管益处、肾脏保护及风险
Postgrad Med. 2025 Sep 9:1-13. doi: 10.1080/00325481.2025.2548199.
9
Pain and Analgesic Use in Patients With Chronic Kidney Disease Not on Dialysis: A Systematic Review.未接受透析治疗的慢性肾脏病患者的疼痛与镇痛药物使用：一项系统评价
Hemodial Int. 2025 Jul 23. doi: 10.1111/hdi.70013.
10
Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease.用于患有（或正在发展为）慢性肺病的早产儿的静脉或肠内袢利尿剂。
Cochrane Database Syst Rev. 2000(2):CD001453. doi: 10.1002/14651858.CD001453.
本文引用的文献
1
Furosemide, an Old Friend of Nephrologists for the Treatment of CKD: Time to Rethink the Relationship?速尿，肾脏病学家治疗慢性肾脏病的老朋友：是时候重新审视这种关系了？
Kidney Int Rep. 2025 May 17;10(7):2094-2096. doi: 10.1016/j.ekir.2025.05.021. eCollection 2025 Jul.
2
Furosemide and Serum Protein-Bound Uremic Toxin Concentrations in Patients With CKD.慢性肾脏病患者中呋塞米与血清蛋白结合尿毒症毒素浓度
Kidney Int Rep. 2025 May 2;10(7):2165-2177. doi: 10.1016/j.ekir.2025.04.040. eCollection 2025 Jul.
3
Diuretics and mortality reduction in incident dialysis patients: a two-year observational study.利尿剂在新进入透析患者中降低死亡率的作用：一项为期两年的观察性研究。
Sci Rep. 2024 Nov 10;14(1):27447. doi: 10.1038/s41598-024-65643-8.
4
Loop diuretics improve conditions of dialysis inception in advanced CKD: an observational cohort study.在 ADVANCED CKD 中，噻嗪类利尿剂改善透析起始条件：一项观察性队列研究。
J Nephrol. 2023 Sep;36(7):2047-2056. doi: 10.1007/s40620-023-01752-3. Epub 2023 Sep 28.
Zotero 插件